Fennec Pharmaceuticals Inc.
FENC
$6.01
-$0.27-4.30%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 97.28% | 94.40% | 110.34% | 110.91% | 32.34% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 234.15% | -53.31% | -33.69% | 9.81% | 92.62% |
| Total Other Non-Cash Items | 76.41% | 52.51% | -28.19% | 17.50% | 22.46% |
| Change in Net Operating Assets | 349.97% | 373.79% | 984.55% | 22,726.92% | -714.51% |
| Cash from Operations | 257.38% | 223.63% | 207.99% | 232.25% | 5.07% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | 2,790.17% | -80.14% | -80.14% | -80.14% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3.21% | 4.43% | 19.43% | 89.17% | 84.91% |
| Repurchase of Common Stock | -728.21% | -634.83% | 41.91% | 64.02% | 59.79% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -894.29% | -894.29% | -- |
| Cash from Financing | -305.11% | 149.83% | -76.35% | -74.59% | -67.98% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 227.23% | 260.90% | 65,239.53% | 24,933.59% | -492.86% |